5.23
+2.15%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medexus Pharmaceuticals
Its shares trade on Toronto Stock Exchange under the ticker MDP.TO. It has been listed since 3 March 2012. In the fiscal year to 31 March 2025, it reported revenue of $108.3m and net income of $2.2m. At that date it held total assets of $171.8m and shareholders' equity of $52.1m.
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Bolton, Ontario. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. The firm is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The firm has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Mar 2012
- Employees
- 98
- Website
- medexus.com/en_US ↗
Leadership
Pay as last reported
- Mr. Michael MuellerIndependent Chairman of the Board$151,643
- Mr. Ken D'entremontChief Executive Officer, Director, since 2018$1.2m
- Mr. Brendon BuschmanChief Financial Officer$443,582
- Mr. Richard LabelleChief Operating Officer$572,774
- Mr. Ian Wildgoose BrownGeneral Counsel, Corporate Secretary$461,406
- Dr. Harmony GargesIndependent Director$130,391
- Mr. Benoit GravelIndependent Director$145,391
- Mr. Stephen NelsonIndependent Director$137,891
- Ms. Nancy PhelanIndependent Director$130,391
- Mr. Menassie TaddeseIndependent Director$137,891
- Ms. Victoria RutherfordInvestor Relations, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medexus Pharma Canada focuses on rheumatology and allergy treatments in Canada with Metoject and Rupall products.
- Medexus Pharma USA targets rheumatology and auto-immune diseases with a strong commercial infrastructure in the US market.
- The company's rare disease treatment portfolio addresses unmet medical needs in oncology and hematology segments.
Weaknesses
- The company employs only 98 full-time employees, limiting operational scale and market reach.
- Medexus Pharma Canada's product lineup includes Metoject and Rupall, which may face competition in established therapeutic areas.
- The firm's focus on rare disease treatments could restrict broader market opportunities in more common conditions.
Opportunities
- Expanding Medexus Pharma USA's presence in rheumatology and auto-immune diseases could capture more market share in the US.
- The growing demand for specialty oncology treatments in Canada presents an opportunity for Medexus Pharma Canada.
- Developing new products for dermatology and allergy segments could leverage existing commercial infrastructure.
Threats
- The pharmaceutical industry faces intense competition from larger firms with more resources and broader portfolios.
- Regulatory changes in Canada and the US could impact the approval and marketing of Metoject and Rupall products.
- Economic downturns might reduce healthcare spending, affecting demand for specialty treatments like Cuvposa and Pediapharm Naproxen Suspension.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.